Latest News

Showing page 1 of 2 pages
1 2 ]
11 April 2018
We are pleased to announce the successful completion of a three-day inspection by the United States Food and Drug Administration (FDA) of our bioanalytical facility in York.
03 October 2016
We are pleased to announce that YBS underwent another successful routine GLP/GCP compliance inspection by the MHRA of our facilities in York on 15-16 September 2016.
01 June 2016
As part of Unilabs York Bioanalytical Solutions’ (Unilabs YBS) commitment to providing an unparalleled service to its clients, YBS is pleased to announce a significant expansion of its Metabolism and Discovery Services facility based at Discovery Park in Sandwich Kent.
01 May 2014
We are pleased to announce that YBS underwent a successful routine GLP/GCP compliance inspection by the MHRA of our facilities in York on 24-25 April 2014.
25 March 2013
Unilabs announced today the two-year status on testing in Europe and several other markets outside Europe with the CE marked ELISA test STRATIFY JCV®.
21 March 2012
During this first year of operations, Unilabs has tested more than 30,000 samples from approximately 2,000 neurologists in 43 countries.
08 November 2011
Dr Tim Leunig explores the ramifications of Pfizer shutting its operations in Kent, and examines the choices on hand for locals.
19 October 2011
As part of Unilabs York Bioanalytical Solutions’ (Unilabs YBS) commitment to providing an unparalleled service to its clients, YBS is pleased to announce the opening of a new facility on the Discovery Park in Sandwich Kent. The new facility will offer discovery bioanalysis and biotransformation services.
28 June 2011
Unilabs has been selected by Biogen Idec to provide a companion diagnostic anti-JCV antibody assay test, called STRATIFY-JCV. The test is a highly sensitive two-step ELISA assay used to detect anti-JCV antibodies. The presence of anti-JCV antibodies is one in a three-factor risk stratification algorithm, along with prior immunosuppressant use and treatment duration, used to calculate the risk of TYSABRI-treated patients developing progressive multifocal leukoencephalopathy (PML).
19 April 2011
Unilabs York Bioanalytical Solutions (YBS) has a history of employing cutting edge technology to maintain its place as Europe’s premier, independent bioanalytical facility.